|drug696||CVnCoV (Dose level confirmed in Part 1) Wiki||1.00|
|drug2588||Pneumococcal vaccine Wiki||1.00|
|drug698||CVnCoV 8 μg Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This study aims to assess efficacy and safety outcomes of a model of abortion care implemented in response to the COVID-19 pandemic. The study involves telehealth for counseling and information, to maintain social distancing, but requires participants to pick up their medications in the clinic in keeping with the Food and Drug Administration's (FDA's) Risk Evaluation and Mitigation Strategy (REMS) requirements. The study will compare efficacy of this model to usual in-clinic care based on published rates. It will also investigate participant acceptability and feasibility of this model of care.
Description: The proportion of participants who have a successful abortion defined as complete abortion without continuing pregnancy, need for manual vacuum aspiration or an additional round of treatment to complete the abortion.Measure: The proportion of participants with a successful abortion Time: Documented resolution of pregnancy, for most patients assessed at 7 days
Description: The proportion of participants reporting being satisfied or very satisfied with telehealth for abortion.Measure: The proportion of participants reporting satisfaction with telehealth for abortion Time: Documented satisfaction measured at approximately 4 weeks follow up
Description: The proportion of participants reporting they would use the telehealth option again if neededMeasure: The proportion of participants reporting they would use the telehealth option again if needed Time: Documented at approximately 4 weeks follow up
Description: The total percentage of participants who carried out the study tasks as directed.Measure: The total percentage of participants who carried out the study tasks as directed. Time: Documented at the 7 day follow up survey
Description: Major adverse events, either reported by the patient or documented through clinical records. Major adverse events will be defined as any abortion requiring blood transfusion, surgery, or hospitalizationMeasure: The total percentage of participants who experienced a major adverse event Time: Assessed at the 7 day and 4 week follow up surveys or any unscheduled contacts from participants
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports